Callouts & quotes from 37,061+ activist slides

"“I’m actually working with Ginkgo because all the research is still done at Ginkgo; Allonnia resides within Ginkgo. Saying that officially or on paper, I guess...Allonnia is a small company. Right now, there are six full-time employees...I think two of them were hired—the CEO was hired in October of 2020. So, officially, it's less than a year-old company.” — Current Allonnia employee; “In some cases, yes, but that is between Allonnia and Ginkgo. I think that may be confidential. I don’t want to speak on that, but yes, they do provide G&A to some extent...My understanding is that in the beginning, they do help with the financial and the hiring and everything.” — Current Allonnia employee"

""We expect China to eventually be $100 million revenue, so we will gain the leverage there." — CEO Ridge, Q1 2016; "Today, the China market is our third largest market for WD-40 in the world." — CEO Ridge, 2018 Shareholder Meeting; "We made an investment in China 14 years ago to open our own subsidiary there. China is now the second largest market in the world for our blue and yellow can with the little red top. We anticipate we'll continue to see double-digit growth in China going forward." — CEO Ridge, Q4 2019; "In China, net sales in U.S. dollars decreased to $2.3 million in the first quarter, down 23% compared to last year due to the timing of customer orders." — CEO Ridge, Q1 2020"

"Alejandro Scannapieco (CFO): "[The] growth. . . it's pretty much organic. . . we have some tailwind from the acquisitions. But keep in mind that PointSource and Ratio were very small tuck-in acquisitions. . . So, pretty much the growth is organic. . . So, the growth remains mostly organic and within relationships that we have been forming. . . looking into 2018, we're very optimistic about keeping up with this level of organic growth." "We have been able to keep up with this 20%-plus growth steadily. We're still aiming to have that 20%-plus organically. . . That's the way to go and how we're going to be growing this company organically on a 20%-plus rate." — Alejandro Scannapieco (CFO)"

"CFO Allais: "And while we're not providing 2022 guidance here, we currently expect OpenSlate to contribute between $15 million and $18 million of revenue in 2022." — OpenSlate Nov 2021; Barclays Analyst: "And then like M&A for you is more tuck-in, it's not like -- there's nothing transformational you can do there?" — Barclays Conf. Dec 2022; CEO Zagorski: "I just don't think we need to do transformational right now. We've got so much core growth to do right now. It sounds like how do we make it go faster." — Barclays Conf. Dec 2022; CFO Allais: "And I think that accelerates organic growth and just kind of continues our opportunity for what we are looking for." — Barclays Conf. Dec 2022"

"We've been successful at rolling out higher price increases, although, it's modest increases relative to what we've done in the past. I would say in the third quarter, price increases contributed a comparable amount to what they've contributed in recent quarters. So across all product areas, price increases represented mid- to high 30% of new recurring sales within the index, it was 40% plus which is consistent with what we've seen in recent quarters. Clearly, there are varying degrees of pushback depending on the product and region and client type, and we are very cognizant of the fact that many of our clients are feeling pressure in the current environment. — CFO, Q3'23 Earnings Call"

""We believe board independence is essential to good corporate governance. In addition to having a board's majority made up of independent members, we generally prefer an independent board chair" — Capital Group. "Northern Trust generally leaves the choice of chairman to the board's discretion... However, Northern Trust will vote case by case on whether to support shareholder resolutions seeking the separation of chairman and CEO" — Northern Trust. "MFS believes boards should include some form of independent leadership responsible for amplifying the views of independent directors and setting meeting agendas, and this is often best positioned as an independent chair of the board" — MFS."

"On July 8, 2022, the Company closed a secured $75.0 million credit agreement with Fairfax Financial Holdings Limited and certain of its affiliates (collectively, “Fairfax”) (the “Facility”). The Facility bears interest at a rate of 6% per annum and will mature on January 31, 2025. The net proceeds of the Facility are being used for working capital and general corporate purposes. As of September 30, 2023, the Company has drawn $75.0 million against the Facility (see note 8 to the interim financial statements for further information). Fairfax has also committed to provide financial support to the Company for the next twelve months to fund loses as required. — Farmers Edge 2022Q3 FS, p.9"

"On May 17, 2020, the Company entered into a purchase agreement with the sole member of Smart2Pay, a payment services provider headquartered in The Netherlands, to acquire all of the sole member's ownership interest for total consideration of approximately $240,001 (€221,567). The total consideration is expected to be settled with a cash consideration of $66,689 (€61,567) and the remaining balance will be paid either by issuance of a convertible debenture of $173,312 (€160,000) or by the issuance of shares of the Company, for which a final determination has not yet been made. The closing of the transaction is subject to certain customary conditions. — Nuvei IPO Prospectus at Sedar.com"

"TAKEDA, lead scientist: spent a year trying to find uses for the instruments and now it’s barely used; dismayed at lack of evidence/data proving its value; unusable for early stage drug discovery; negligible TAM; just an overpriced mash-up of cheap, commonplace lab tools; emerging competitors are cheaper and better. — Takeda Lead Scientist. HARBOUR BIOMED, former executive closely involved in purchase says they would have sent it back for a refund if they could; 80-90% failure rate for complex antibodies; “lot of false positives” and errors; cost to buy and operate is out of control; BLI can’t support the machine and staff seemed out of their depth. — Harbour BioMed Former Executive."

""...we're disclosing patient base numbers for the first time - so investors and analysts alike can kind of reset their bar in their models - between 140,000 and 150,000 patients around the world." — JP Morgan Healthcare Conference (1/12/16); "Our worldwide patient base we now peg at about 200,000 patients." — JP Morgan Healthcare Conference (1/10/17); "Last year we set a patient base goal at this conference saying we would exit this year with approximately 270,000 patients in our patient base and we have achieved that goal as well." — JP Morgan Healthcare Conference (1/9/18); "...we're not going to talk about the install base or the patient number." — Q4 FY18 Earnings Call (2/21/19)"

""Cross-shareholdings have been a point of contention for Group parent companies like Toyota, as have parent-child listed subsidiaries and persistently low valuations." — Asset Value Investors, April 2025; "In the stock market, it has been pointed out that [cross-shareholding as exemplified in Toyota Group] leads to a decline in corporate governance." — Sumitomo Mitsui DS Asset Management, December 2023; "It can be said that not only is there concern that extensive cross-shareholdings within these groups disregard the interests of minority shareholders, but they also contribute to the decline in capital efficiency in the automotive industry." — Nomura Asset Management, September 2023"

"“Well, again, you're right, we've all used it. I used it in the early '90s and saw the hypertrichosis, which was very, very bad in young women. There are also actually some jaw changes that occur with prolonged use. And it is a drug, not without risk. And like anything else, you have to balance the risk of the disease versus the risk of the drug. They're a one-trick pony at this point. I don't know what the genesis of the idea for the drug was. I have no idea where this came from, why there were some original trials or thoughts about it. But as I said, at this point, am I going to use it? No, I'm not going to use it.” — Pediatric endocrinologist, division chief at an academic center"

""It will be interesting over the six to nine months to see how the software responds to the scale that Meta wants and that Pure is talking about because it's never been run at a fraction of the scale they're talking about. Pure doesn't know what's gonna happen when it reaches that scale. [It] would concern me that I have this customer consuming my software at a scale that none of my other customers do...that I now need to devote significant engineering time to serve that. And I'm going to be coming up with code that is not relevant to 99% of my customer base. At what point do I become beholden to Meta for my engineering path because of this deal?" — CTO at storage system competitor"

"“It’s an interesting market. I was going over some stuff the last time I really dove deeply into this. For example, the top competitors for Twist are GenScript, Thermo Fisher - sometimes people refer to them as GeneArt, and IDT - and these are big companies that have been around a long time. Sometimes to get a contract, we had an experience at Gen9 that GenScript, for example, would just find out what we quoted and undercut the quote. And then, our understanding of the market was GenScript tended to throw more people on a project because they have a low waiver cost in China.” — Executive recently at IDT, a key Twist competitor; currently employed at another synthetic biology player"

"[I]t is unusual for an executive chairman to be compensated at a significantly higher level than the company's CEO and the proxy does not provide a compelling reason for this arrangement... The proxy does not adequately explain why investors should bear the costs for him to remain the most highly compensated NEO even when his apparent role and responsibilities within the company are reduced. — Institutional Shareholder Services – 2021 Disney Report; [W]hile we acknowledge the need to retain critical leadership in anticipation of such a significant merger, the magnitude of the special equity grant ($100 million) is excessive. — Institutional Shareholder Services – 2018 Disney Report"

""We’ve had new investors come in over the last couple of years based on what they saw us doing in Midstream. And we want to share that gospel with everyone out there that we are committed to that business." — Mark Lashier, Goldman Sachs Conference, January 1, 2025; "I met with management and told them. I think their assets are great – Permian, DJ – I would love to invest. But, I can’t own Phillips for the look through midstream. I would get killed versus my benchmark any time cracks moved. They need to separate the midstream business out and then I am there. I would allocate hundreds of millions if I could buy it separately, but not today." — Large Midstream Investor (>$5bn in AUM)"

"“We’ve had new investors come in over the last couple of years based on what they saw us doing in Midstream. And we want to share that gospel with everyone out there that we are committed to that business.” — Mark Lashier, Goldman Sachs Conference, January 1, 2025; “I met with management and told them. I think their assets are great – Permian, DJ – I would love to invest. But, I can’t own Phillips for the look through midstream. I would get killed versus my benchmark any time cracks moved. They need to separate the midstream business out and then I am there. I would allocate hundreds of millions if I could buy it separately, but not today.” — Large Midstream Investor (>$5bn in AUM)"

""The fraudulent or otherwise illegal, unauthorized, or improper act or process of an individual, including a caregiver or fiduciary, that uses the resources of an older individual for monetary or personal benefit, profit, or gain, or that results in depriving an older individual of rightful access to, or use of, benefits, resources, belongings, or assets." — Older Americans Act of 2006; "Elder financial abuse is big business. It’s estimated that older adults lose more than $36 billion every year to scams, fraud and exploitation. It’s even more alarming that almost half of that money is lost due to tactics that – while deceptive in nature – are technically legal." — Medicare website"

"“The alienation...some of us really hate Waleed because we just think he’s dishonest with the way he talks...and he gets angry when people say, no, we’re not getting reimbursed, and it pisses him off and his people off. They always get angry at the meetings when people get up and say, yeah, but we actually did a financial analysis, and Duke University did a beautiful analysis - they presented it at the meetings where they showed how much of a hit they took with TransMedics liver use at their center. They presented this at one TransMedics user meeting, and then they've also presented it at a symposium at the ATC.” — Prominent surgeon, Director of a leading academic transplant center"

"In the fourth quarter of 2007, [Bristol-Myers] announced its intent to transform into a next generation biopharma leader by implementing a strategy that is referred to as the "String of Pearls" initiative. Pursuant to this initiative, [Bristol-Myers] is focused on entering into a series of transactions, including acquisitions, licensing agreements, joint ventures and other business arrangements, that are intended to enrich [Bristol-Myers]' pipeline, technology, capabilities and talent. Therefore, [Bristol-Myers] continues to look for opportunities to complement its internal capabilities with external innovation. — Bristol-Myers Tender Offer Statement of Kosan Biosciences, May 2008"

"If we assume $2-million for the Beacon, and the way I have to justify it is actually $3-million because of the $2-million purchase price, then we'll probably keep it for about five years, and you have to have a service contract, which is around 8% to 12% of your purchase price, so that adds around another million bucks just for a service contract. You definitely need FTE's for it. When I'm looking at new technology, a new piece of equipment, that's something that I think about when I talk to these groups, is, do I need to hire somebody that has a special understanding just to run this piece of equipment? Because if so, then that's more of an uphill battle for me. — Lonza scientist"

"We have transformed before, adding things like WiFi, larger bins and in-seat power, and we will continue to adapt as needed. — CEO Bob Jordan, April 2024; ... We’re not convinced [these] drive share shift when Southwest fails to offer a pricing advantage vs. a nonstop competitor. — J.P. Morgan, April 2023; In-seat power, larger overhead bins and Wi-Fi are table stakes... — Cowen, April 2024; ...Management reduced [their guidance] to $1.0 to $1.5B (vs $1.5B) of pre-tax profit improvements from network optimization and other initiatives. However, on our revised outlook, we’re now modeling $0 benefit in 2024... Network optimization so far has been inadequate... — Seaport, April 2024"

"“The real world results that Nevro had in the field didn’t live up to the clinical data they were purporting. They found themselves in a bind. The initial response was to try and re-educate doctors on why it would work because the data says it would and they just need to keep believing.”; “Nevro’s paresthesia-free message doesn’t resonate anymore. Competitors have waveforms that mimic paresthesia-free pretty closely. Boston Scientific and Abbot for sure. Or they have paresthesia-light. Abbott brought out paresthesia-light with the Burst DR platform. It’s been out for a few years now. Boston Scientific has Wavewriter.” — Former Nevro regional sales director now at a key competitor"

""was so young and it was just really gross and sad" because "it was very clear to all at the pool that she was paid to be there." — TripAdvisor user regarding Sofitel Cartagena. "at night the call girls used to sit in the lobby and people were taking them to the room and partying all night." — TripAdvisor guest regarding Sofitel Dubai Jumeirah Beach. "we were surprised when we saw many "prostitutes" at the bar and at the swimming pool, smoking "chicha" seducing and hanging with men from Gulf countries : it was disgusting." — Guest regarding Sofitel Agadir. "couldn't walk around without being groped" and she observed "multiple sex workers." — Reddit user regarding Sofitel Bangkok."

"At its FY22 results BP announced a capex increase of $1bn pa for its Resilient Hydrocarbons whilst increasing its 2030 production target by 0.5mmboed. Using this as a proxy implies that targeting 2030 production of 2.5mmboed as opposed to 2.0mmboed requires additional capex of $1bn pa in upstream production. Using BP average capex spent on upstream production in 2021 and 2022 where BP spent on average capex of $3.7bn per 1mmboed of oil and gas produced implies that targeting 2030 production of 2.5mmboed as opposed to 2.0mmboed requires additional capex of $1.8bn pa in upstream production. We use a value of $1.5bn pa which sits in the middle of these two approaches. — Footnote 56"

""It's not exactly science, what they're doing," says Christopher Monroe... "It's high-level engineering, and I think it's high-level salesmanship, too"... "There's no evidence that what they're doing has anything to do with quantum mechanics," he says. — Christopher Monroe (2013). "The big quantum computing discoveries that will most impact society are still years away. In the meantime, we will see breathless announcements of records broken... But too much hype risks disillusionment that may slow the progress." — Christopher Monroe (2019). "The field is still waiting for something that's useful and having only about 15 qubits is maybe not so useful." — Christopher Monroe (2012)."

"We have transformed before, adding things like WiFi, larger bins and in-seat power, and we will continue to adapt as needed. — CEO Bob Jordan, April 2024; ...We’re not convinced [these] drive share shift when Southwest fails to offer a pricing advantage vs. a nonstop competitor. — J.P. Morgan, April 2023; In-seat power, larger overhead bins and Wi-Fi are table stakes... — Cowen, April 2024; ...Management reduced [their guidance] to $1.0 to $1.5B (vs $1.5B) of pre-tax profit improvements from network optimization and other initiatives. However, on our revised outlook, we're now modeling $0 benefit in 2024... Network optimization so far has been inadequate... — Seaport, April 2024"

"I think the market is very different than the way folks have thought about this market. I think it's very different than the way our competitors even think about the market, to be honest with you...The market is not 6.5 million ACM tests being performed each and every year. The market is further up the care pathway. It has to happen in primary care. You have to do this through population health programs, value-based care. That's right where we're going...And that's why I think the market is 27 million-plus patients by the time we get it opened up. So we're incredibly bullish about that and feel good about the momentum. — iRhythm CEO Blackford at Goldman Sachs Conference, 6/10/25"

"We have transformed before, adding things like WiFi, larger bins and in-seat power, and we will continue to adapt as needed. — CEO Bob Jordan, April 2024; ...We’re not convinced [these] drive share shift when Southwest fails to offer a pricing advantage vs. a nonstop competitor. — J.P. Morgan, April 2023; In-seat power, larger overhead bins and Wi-Fi are table stakes... — Cowen, April 2024; ...Management reduced [their guidance] to $1.0 to $1.5B (vs $1.5B) of pre-tax profit improvements from network optimization and other initiatives. However, on our revised outlook, we're now modeling $0 benefit in 2024... Network optimization so far has been inadequate... — Seaport, April 2024"

"“Costs associated with a specific real estate project are capitalized during the development period. We capitalize costs directly associated with development and construction of identified real estate projects. Indirect costs that clearly relate to a specific project under development, such as internal costs of a regional project field office, are also capitalized. We capitalize interest (up to total interest expense) based on the amount of underlying expenditures and real estate taxes on real estate projects under development. If we determine not to complete a project, any previously capitalized costs are expensed in the period such determination is made.” — 2009 10-K, page 26"

"3M is offering me cases at a $500 lab fee compared to my Invisalign Lab fee of $1,000. If I can start doing more cases with 3M and it will save me money, why not just switch? 3M software is excellent. It is very easy to use. They brought a lot of people over from Invisalign. It’s getting to the point where it will be as good as Invisalign. — Orthodontist, Diamond Plus Align Tier; 3M came to me and said that we can do all of your cases for $600... I expect my Invisalign volumes to be down going forward — Orthodontist, Diamond Plus Align Tier; We are going to see major price compression with lab fees in the next one to two years. — Senior Employee, Major Dental Equipment Supplier"

"3M is offering me cases at a $500 lab fee compared to my Invisalign Lab fee of $1,000. If I can start doing more cases with 3M and it will save me money, why not just switch? 3M software is excellent. It is very easy to use. They brought a lot of people over from Invisalign. It's getting to the point where it will be as good as Invisalign. — Orthodontist, Diamond Plus Align Tier; 3M came to me and said that we can do all of your cases for $600... I expect my Invisalign volumes to be down going forward — Orthodontist, Diamond Plus Align Tier; We are going to see major price compression with lab fees in the next one to two years. — Senior Employee, Major Dental Equipment Supplier"

"With Phillips, what can they do now that will help them longer-term? In terms of execution, I want them to have a much more independent board. I want them to spin off the CP Chem business or sell it to Chevron. I want them to spin-off the retail business. They are actually selling off the Jet part, which is the retail part, so that's good. I want them to continue divesting. I want them to not have a conglomerate discount. They have a conglomerate discount, but for all the wrong reasons. They just have too many unrelated businesses, and I think that's just not good for them longer-term and it is not good for us. Also need to get rid of midstream. — Third-party Shareholder Survey"

""We will anticipate that this reconciliation will take another six months of mining in the main mineral domain to be able to clearly reconcile our mineral resource to grade control and our reserve estimate to plan feeds." — July 2016 (AKG, 2Q16 Earnings Call Transcript, 2060720). "We started to open up and now are getting into that main sandstones on to mineralization and the first month that we were mining that reconciliation was awful..." — November 2016. "Due to the complexity in planning a schedule for 11 different pits and the detailed design process, we now anticipate publishing the expansion feasibility study in Q2 2017." — February 2017 (AKG, Press Release, 2017-02-24)."

""And so while I do believe smart implants and wearables is a big part of the future, which is why we did the Orthosensor acquisition, and we'll continue to pursue this. I think it's going to take time for this to really demonstrate the value because what data are you collecting? ...And there are a lot of question marks today. I think the data is going to be useful, but we have to be able to turn that data into something that actually validates the need for it. And we're not at that stage yet. So I think this will be something that will grow over time, but it's not something that's going to transform the market in a very, very fast period of time." — CEO Lobo, MS Conf, Sept 2021"

"“we use their national NOP program for all of them.” — Transplant hepatologist and director of the liver program at a Midwest academic center; one of TransMedics highest volume users. “to be completely candid, this is a very small world and I don't know of any program that uses them that doesn't use the NOP.” — Transplant hepatologist and director of the liver program at a Midwest academic center; one of TransMedics highest volume users. “you don't have access to their pump” — Transplant surgeon and surgical director at a high volume academic center in the western US; also medical director at a major OPO (organ procurement organization); one of TransMedics highest volume users."

"Scott D. Farmer, Cintas's Chairman and Chief Executive Officer, stated, "We are pleased with these fourth quarter financial results which conclude a very successful year. For the ninth consecutive year, our organic revenue growth was in the mid- to high- single digits and EPS grew double digits when adjusted for one-time and special items. Additionally, our strong cash flow and balance sheet enabled us to deploy cash to increase shareholder value. In fiscal 2019 we paid an annual dividend of $220.8 million that increased 26.5% over the prior year, and we purchased 4.8 million shares of company stock in a total amount of $953.4 million." — Fiscal Year 2019 results press release"

"there are different frameworks for looking at the same issue. Objectively, it's true that it's a shorter procedure with presumably lower incontinence rates and ejaculatory dysfunction. But I think that there will remain other procedural options there for a lot of men. And I think that another big thing to consider with Aquablation is that the long-term data is just not out there yet. And so we don't know 10-year data on recurrence rates of prostate regrowth...I just feel hesitancy because, in the history of the BPH marketplace, so many procedures come out every five or ten years and most of them don't stick. — Spruce Point Interview with Community Hospital Urologist, Nov 2024"

"To be completely frank and honest with you, the products in general are very, very behind when it comes to innovation. DIY hasn't taken off yet. Again, this is where maybe I'm jaded. I don't feel like I am. I feel like I'm reading this from a rational perspective. I think that Snap is so far behind that they're never going to be able to truly catch up, especially once Matter takes off. — Former Snap Employee (2023); Until now, smart home technology hasn't been easy enough to use for most people — or affordable enough for many to consider. This launch brings us closer to helping everyone feel ready and confident to get started. — David Granath, Range Manager at IKEA of Sweden."

"We have transformed before, adding things like WiFi, larger bins and in-seat power, and we will continue to adapt as needed. — CEO Bob Jordan, April 2024; We’re not convinced [these] drive share shift when Southwest fails to offer a pricing advantage vs. a nonstop competitor. — J.P. Morgan, April 2023; In-seat power, larger overhead bins and Wi-Fi are table stakes... — Cowen, April 2024; ...Management reduced [their guidance] to $1.0 to $1.5B (vs $1.5B) of pre-tax profit improvements from network optimization and other initiatives. However, on our revised outlook, we’re now modeling $0 benefit in 2024... Network optimization so far has been inadequate... — Seaport, April 2024"

""Vanderbilt is the biggest heart transplant program not in the country but in the world. The volume is gigantic. They do zero TransMedics...they are so upset...they hate the company." — Transplant surgeon at Vanderbilt. "I know I can’t use it too much, or I’m not going to be making any money, and then I’m not going to have a job...if a hospital thinks they’re losing money by providing a service, are they really going to go out and provide a service? So, that’s why I said I had to have an actual financial talk with my head of finance and describe the margins and how they’re doing." — Transplant surgeon and transplant program director at a major academic center in Pennsylvania."

""...what happens when the OEMs themselves do all of these things. There's cameras in every vehicle that's rolling off a lot right now. There's cellular connectivity in every vehicle... It's been really disruptive in this past year. It's been loomingly disruptive, I think, for the past handful of years, but it's going to continue to get more traction, which will in turn drive prices down on the basic, again, telematics function, location, driver behavior, stuff like that...I think OEM is more disruptive in the light-duty space because in the light-duty space for an OEM, your use case is a little smaller." — Tegus Interview with Associate VP of Carrier Sales at Geotab, 7/31/23"

"I think we'll probably stop using it...the idea that their device is the premier and one and only best device that is on the market and that can be used to save human life is not true simply because the market has shifted...the clinicians who have been very, very concerned about the poor business practices and misalignment of incentives with TransMedics, that there are now going to be other technologies that are coming up that actually...it's very promising that there's going to be a different option, not only from the actual product standpoint but just from a business standpoint, I would switch right away. — Veteran transplant administrator at Massachusetts General Hospital"

"The Board also approved annual base salary increases for the Company's executive officers as part of its annual performance review, including Ernie Garcia III, the Company's Chief Executive Officer, whose annual base salary was increased from $400,000 to $885,000, Mark Jenkins, the Company's Chief Financial Officer, whose annual base salary was increased from $375,000 to $735,000, and Benjamin Huston, the Company's Chief Operating Officer, whose annual base salary was increased from $375,000 to $735,000. The salary increase were approved retroactively to January 1, 2019, consistent with the Company's practices for annual merit increases. — Carvana Co. (implied from context)"

"Their graphs are not consistent. You should be consistent with the cells, same size, from the same batch, or from a different batch with the same size. That's weird to me. — Former employee. It's very easy to tweak each of those specs in order to get a good result. I's easy to change the pressure of the battery, change the temperature the battery's performing at, and you can get different cycle results, depending on which one you're showing... — Second ex-employee. If you've got it all working together, are you cherry-picking different elements? You're trying the separator in one; you're trying the anode in another; you're trying the cathode in another. — Third ex-employee."

"“The rate limiter on [a new strategy] is the CEO. I don't have a lot of confidence he is the right person at this stage... The Street would be widely supportive of a change.” — Southwest Shareholder; “I have zero confidence this team can get this right... I rarely call for wholesale change at a company, but that is what is needed here.” — Southwest Shareholder; “The CEO is a headwind to a turnaround. Firing him is the tailwind.” — Southwest Shareholder; “I would rate them as the worst performing management team in airlines. This was a company that has destroyed more value based on their own inaction than anyone else in the industry. They need to go.” — Southwest Shareholder"

""Meredith said the first ground firing of a GEM-63 motor is scheduled for mid-2018, and the booster will be ready for Atlas 5 launches by the end of 2018." — Source; "In the fifth paragraph of a press release highlighting its "industry-leading strategic partnerships" for building Vulcan, the company announced it had selected Blue Origin's BE-4 engine for Vulcan, a choice nearly everyone expected." — Source; "Aerojet also produces the hydrogen-fueled RS-68 main engine for ULA's soon-to-retire Delta 4 rocket and still hopes to convince ULA to use the kerosene-fueled AR1 for Vulcan's main stage (ULA, however, has said the lead contender is Blue Origin's BE-4 engine)." — Source"

"There are two commonly accepted structures for independent leadership to balance the CEO role in the boardroom: 1) an independent Chair; or 2) a Lead Independent Director when the roles of Chair and CEO are combined, or when the Chair is otherwise not independent. ... In the event that the board chooses to have a combined Chair/CEO or a non-independent Chair, we support the designation of a Lead Independent Director, with the ability to 1) provide formal input into board meeting agendas; 2) call meetings of the independent directors; and 3) preside at meetings of independent directors. These roles and responsibilities should be disclosed and easily accessible. — BlackRock"

""So RFID is a -- today is low single-digit percent of the overall portfolio in terms of revenue. But we're excited about the combination -- actually with the combination of RFID and locationing solutions. As a combined business, we think, it can grow in the mid-teens here for the near future." — CFO Winters, JPMorgan Conf. May 23, 2022. "We're the global leader in enterprise mobile computing. We're the global leader in industrial printing. We're the global leader in data capture or scanning. We're the global leader in RFID reading. And that matters to our customers because they want to do business with the leader in the industry." — CEO Burns, Innovation Day May 14, 2024."

""The other problem that we have is that there's constant change in both the software version that's being deployed or supported, there are hardware changes, and so we feel like—we get to where everything's been updated, we're ready to start running the experiment, something goes wrong, they come out to maintain the instrument, and it's like, 'Oh, by the way, we've changed the software again. We're going to update the version.' And then it's something different, and so, we have to go back and kind of start over and say, now how does this version of software function? What sorts of bugs are we going to find?' wasn't worth it." — Leading academic institution/ex-BLI scientist"

""The timing just worked very well for us right now. K2M has really developed stronger and stronger performance with their new product launches. So the timing just came together right now.... And so I'm very optimistic about the 2 organizations merging very well and performing very well." — Stryker CEO Lobo, Q3 2018 Conf Call. "We expect mid-single-digit performance on a pro forma basis. And then obviously, in 2020, that'll then roll into organic. So we're really excited with the speed of that integration and being able to post these numbers with a Spine business that's been essentially flat for the past 5 years is pretty remarkable." — Stryker CEO Lobo, Q4 2018 Conf Call."

"I would like to touch on the management fee reduction we announced in December. First of all, the Erie Indemnity Company Board of Directors sees the management fee as a tool to balance the interest of the shareholders, of the Erie Indemnity Company with the policyholders of the exchange. Keep in mind the exchange assumes 94.5% of the total underwriting risk and is the only corporate customer of the Erie Indemnity Company. Given the strong revenues and earnings growth of the Erie Indemnity Company and the underwriting loses we are experiencing at the exchange, the Board opted this past December to reduce the management fee from 25 to 24. — Jeffrey Ludrof, Former President"

"“For kidney, there’s actually been pumping technologies, portable perfusion devices that have been around for literally 40 years, and that’s a good example of a technology that’s similar to TransMedics. But despite the fact that kidney transporting technology has been around for 40 years, less than 40% of kidneys in the United States per year are pumped for financial reasons. All of these companies - XVIVO, LifePort - had to segue to liver transplantation...because those are the fields that there are tens of thousands of transplants as opposed to just a few thousand hearts and lungs per year.” — Prominent surgeon, Director of leading West Coast academic transplant center"

"“Yeah, they should be. And for Prader-Willi, I don't think you'd need to worry so much about titrating it to a certain level and things, because it's not the sugars we're worried about, it's just being able to dampen the hyperphagia response. I think even if, say, they were on the same oral suspension and you were worried about peak levels or whatever, you still wouldn't really need to give it two to three times daily, I don't think, because it's a different —” “Yeah, I would have thought so. I'd say, you might need to take it to a dose and then do it. But I would have thought that would be better than a once-daily tablet.” — Trial investigator, pediatric endocrinologist"

""Pretty amazing data, if we say so ourselves" — QuantumScape CEO on Mad Money. "A blockbuster assertion by QuantumScape, not verified by outside scientists, that it was on a short path to a solid state EV battery using pure metallic lithium, a prized material that has been the subject of a decades-long global technology race." — Marker. "Singh says the battery resolved all of the core challenges that have plagued solid-state batteries in the past, such as incredibly short lifetimes and slow charging rate." — Wired. "As far as he's concerned, the company has solved the hard basic-science problems that have stymied the commercialization of a solid-state battery." — Wired."

""[Samsara] really focused on that sweet spot of 25 to 100 trucks. That's where they really initially went to market... And what we found is that Samsara is still, to this date, they're very wide, so they have all of the applications that someone would need, but they're not very deep. And on a 50- to 100-truck fleet, they don't have to be that deep. But you want somebody that has thousands of trucks, they want to customize it, they want to personalize it. And they want some very specifics that Samsara doesn't have the flexibility to do because they're serving all of the markets in a cookie-cutter approach..." — Former Director of Sales, New Business at Omnitracs, 7/29/22"

"Following the announcement on Tuesday that Marathon Petroleum would not spin-off its retail segment, several investors we spoke to expressed greater concern on the story. — Goldman Sachs, September 8, 2017; MPC's acquisition of ANDV creates the largest US refiner and adds significant diversification. However, it comes at a cost, with MPC using its chronically undervalued currency to take out ANDV shares at a price that we think is above intrinsic value. — RBC, May 1, 2018; Marathon Petroleum (MPC) is the stock we receive the most questions on, particularly following recent disclosure of an activist position and subsequent outperformance. — Scotiabank, September 10, 2019"

"What is still missing from the board's discussion [...] is a real sense of what is required to execute on a true, robust strategy because playing catch-up is not in itself a strategy. — Pershing Square / Canadian Pacific ISS report (May 13, 2022). Although there is an elevated bar for supporting a majority slate under ISS' contest framework, this contest amounts to a referendum as to which management team is better suited to run EQT. [...] By contrast, the incumbent management team has failed to advance turnaround efforts at a satisfactory pace for shareholders, has identified target initiatives that are vague and unambitious [...] — Rice/EQT ISS report (Jun. 28, 2019)."

""I wanted to ask about competition... And I'm just wondering if you see any risk of pressure on pricing, whether subscription rates or payments rates?" — CIBC Analyst, Feb 2021. "In all transparency, I think we've never had a better model. So we don't feel pressure from competitors... and we do not feel any pressure right now on pricing for many of our competitors?" — President JP Chauvet, Feb 2021. "We are bundling more and more Payments with our software and our core offering." — President JP Chauvet, Nov 2020. "Along with the discounts that we offer to new customers to join and to adopt new tools. That's obviously -- has an impact on revenue." — CFO Nussey, Aug 2020."

""Slide 6 walk you through a little more about what Peter outlined, that it is our intention within two years of close to list the combined Pigments businesses and do an IPO." — Kimo Esplin, CFO, September 2013; "And I might just add -- and the fourth [quarter] this next year, we will be deconsolidating our TiO2 business and our pigments business." — Peter Huntsman, President & CEO, June 2015; "It is our assumption at this point that our Company will keep a minority economic [interest]...Obviously, we will be spinning off greater than 51% to allow it to be -- as far as the voting control, to allow it to be a tax free spin." — Peter Huntsman, President & CEO, August 2016"